Insights into the relationship between hypertension and albuminuria

Current Hypertension Reviews

Volumn 3, Issue 1, 2007, Pages 29-37

  Hilliard, Lucinda M ^a   Russo, Leileata M ^b   Comper, Wayne D ^c  

^a MONASH UNIVERSITY   (Australia)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Albumin; Albuminuria; Angiotensin II; Cardiovascular disease; Degradation pathway; Hypertension; Microalbuminuria; Renin angiotensin system; Transforming growth factor 1

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUTRALIZING ANTIBODY; OSTEOGENIC PROTEIN 1; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; EPIDEMIOLOGICAL DATA; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MICROALBUMINURIA; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; URINARY EXCRETION;

EID: 34247103999     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340207779815563     Document Type: Review

References (134)

1. Burne MJ, Panagiotopoulos S, Jerums G, Comper WD. Alterations in renal degradation of albumin in early experimental diabetes: A new factor in the mechanism of albuminuria. Clin Sci 1998; 95: 67-72.
2. Greive KA, Balazs DH, Comper WD. Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem 2001; 47: 1717-19.
3. Russo LM, Bakris G, Comper WD. Renal handling of albumin. A critical review of basic concepts and perspective. Am J Kid Dis 2002; 39: 899-919.
4. Strong KJ, Osicka TM, Comper WD. Urinary peptide excretion by non-diabetic volunteers and diabetic patients. J Lab Clin Med 2005; 145: 239-46.
5. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006; 69: 440-9.
6. Bernard A, Viau C, Ouled A, Lauwerys R. Competition between low- and high-molecular-weight proteins for renal tubular uptake. Nephron 1987; 45: 115-8.
7. Christensen EI, Rennke HG, Carone FA. Renal tubular uptake of protein: Effect of molecular charge. Am J Physiol 1983; 244: F436-41.
8. Osicka T, Houlihan C, Chan J, Jerums G, Comper WD. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000; 49: 1579-84.
9. 131-tagged albumin. J Clin Invest 1951; 30: 1228-37.
10. Greive KA, Nikolic-Paterson DJ, Guimaraes MAM, et al. Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol 2001; 159: 1159-70.
11. Schaeffer RC, Gratrix ML, Mucha DR, Carbajal JM. The rat glomerular filtration barrier does not show negative charge selectivity. Microcirculation 2002; 9: 329-42.
12. Guimaraes MA, Nikolovski J, Pratt LM, Greive K, Comper WD. Anomalous fractional clearance of negatively charged Ficoll relative to uncharged Ficoll. Am J Physiol 2003; 285: F1118-24.
13. Holmquist P, Sjobald S, Torfffvit O. Pore size and charge selectivity of the glomerular membrane at the time of diagnosis of diabetes. Pediatr Nephrol 2004; 19: 1361-66.
14. Russo LM, Osicka TM, Brammar GC, Candido R, Jerums G, Comper WD. Renal processing of albumin in diabetes and hypertension in rats: possible role of TGF-beta1. Am J Nephrol 2003; 23: 61-70.
15. Greive KA, Osicka TM, Russo LM, Comper WD. Nephrotic-like proteinuria in experimental diabetes. Am J Nephrol 2003; 23: 38-46.
16. Gudehithlu KP, Pegoraro AA, Dunea G, Arruda JA, Singh AK. Degradation of albumin by the renal proximal tubule cells and the subsequent fate of its fragments. Kidney Int 2004; 65: 2113-22.
17. Feld LG, Brentjens JR, Van Liew JB. Renal injury and proteinuria in female spontaneously hypertensive rats. Ren Physiol 1981; 4: 46-56.
18. Cooper ME, Allen TJ, Jerums G, Doyle AE. Accelerated progression of diabetic nephropathy in the spontaneously hypertensive streptozotocin diabetic rat. Clin Exp Pharmacol. Physiol 1986; 13: 655-662.
19. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Japan Circ J 1963; 27: 282-93.
20. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 39: 77-88.
21. Russo LM, Osicka TM, Bonnet F, Jerums G, Comper WD. Albuminuria in hypertension is linked to altered lysosomal activity and TGF-β1 expression. Hypertension 2002; 39: 281-6.
22. Russo LM, Brammar GC, Jerums G, Comper WD, Osicka TM. The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-β expression. J Hypertens 2003; 21: 419-28.
23. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FH. Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 1992; 41: 107-114.
24. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS. Molecular mechanisms of glucose action on angiotesinogen gene expression in rat proximal tubule cells. Kidney Int 1999; 55: 454-64.
25. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003; 93: P3-13.
26. Harris RC, Akai Y, Yasuda T, Homma T, The role of physical forces in alterations of mesangial cell function. Kidney Int 1994; 45: S17-21.
27. Harris RC, Haraldsson MA, Badr KF. Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics and metabolic activity. Lab Invest 1992; 66: 548-54.
28. Hirakata M, Kaname S, Chung UG, et al. Tyrosine kinase dependent expression of TGF-β induced by stretch in mesangial cells. Kidney Int 1997; 51: 1028-36.
29. Li Q, Muragaki Y, Hatamura I, Ueno H, Ooshima A. Stretch-induced collagen synthesis in cultured smooth muscle cells from rabbit aortic media and a possible involvement of angiotensin II and TGF-β. J Vasc Res 1998; 35: 93-103.
30. Riser BL, Cortes P, Heilig C, et al. Cyclic stretching forces selectively upregulates TGF-β isoforms in cultured rat mesangial cells. Am J Pathol 1996; 148: 1915-23.
31. Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: Involvement of the transforming growth factor-β system. Kidney Int 1998; 53: 631-638.
32. McMahon R, Murphy M, Clarkson M, et al. IHG-2, a Mesangial cell gene induced by high glucose, is human gremlin. J Biol Chem 2000; 275: 9901-9904.
33. Merino R, Rodriguez-Leon J, Macias D, Gañan Y, Economides AN, Hurle JM. The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. Development 1999; 126: 5515-5522.
34. Wang S, Chen Q, Simon TC, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037-2049.
35. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92: 1366-1372.
36. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta1. Kidney Int 1992; 41: 1213-21.
37. Teschner M, Schaefer RM, Svarnas A, Heidland U, Heidland A. Decreased proteinase activity in isolated glomeruli of streptozotocin diabetic rats. Am J Nephrol 1989; 9: 464-9.
38. Olbricht CJ, Geissinger B. Renal hypertrophy in streptozotocin diabetic rats: role of proteolytic lysosomal enzymes. Kidney Int 1992; 41: 966-72.
39. Schaefer RM, Paczek L, Huang S, Teschner M, Schaefer L, Heidland A. Role of glomerular proteinases in the evolution of glomerusclerosis. Eur J Clin Chem Clin Biochem 1992; 30: 641-6.
40. Shechter P, Boner G, Rabkin R. Tubular cell protein degradation in early diabetic renal hypertrophy. J Am Soc Nephrol 1994; 4: 1582-7.
41. Rabkin R, Fervenza FC. Renal hypertrophy and kidney disease in diabetes. Diabetes Metab Rev 1996; 12: 217-41.
42. Schenk O, Ling H, Sebekova K, Vamvaskas S, Heidland A. High glucose media enhance the responsiveness of tubular cells to growth promoters: Effect on lysosomal cathepsins and protein degradation. Miner Electrolyte Metab 1998; 24: 254-60.
43. Russo LM, Comper WD, Osicka TM. Mechanism of albuminuria associated with cardiovascular disease and kidney disease. Kidney Int 2004; 92: S67-8.
44. Gekle M, Knaus P, Nielsen R, et al. Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003; 15: 471-81.
45. Clavant SP, Forbes JM, Thallas V, Osicka TM, Jerums G. Comper WD. Reversible angiotensin II-mediated albuminuria in rat kidneys is dynamically associated with cytoskeletal organization. Nephron Physiol 2003; 93: 51-60.
46. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7.
47. Wolf G, Ziyadeh FN. Renal tubular hypertrophy induced by angiotensin II. Semin Nephrol 1997; 17: 448-54.
48. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56:393-405.
49. Gilbert RE, Wu LL, Kelly DJ, et al. Pathological expression on renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tabulointerstitial fibrosis. Am J Pathol 1999; 155: 429-40.
50. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-107.
51. Yu L, Border WA, Huang Y, Noble NA. TGF-β, isoforms in renal fibrogenesis. Kidney Int 2003; 64: 844-56.
52. Qi W, Twigg S, Chen X, et al. The integrated actions of transforming factor beta-1 and connective tissue growth factor beta-1 in renal fibrosis. Am J Physiol 2005; 288: F800-9.
53. Osicka TM, Forbes JM, Thallas V, Brammar GC, Jerums G, Comper WD. Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats. Nephrology 2003; 8: 205-211.
54. Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890-9.
55. Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80.
56. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996; 45: 522-530.
57. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015-8020.
58. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995; 118: 213-21.
59. Kim HW, Kim BC, Song CY, Kim JH, Hong HK, Lee HS. Heterozygous mice for TGF-betaIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int 2004; 66: 1859-1865.
60. Bigazzi R, Bianchi S, Campese VM, Bladari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992; 61: 94-7.
61. Bianchi S, Rigazzi R, Campese VM. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications. Am J Kid Dis 1999; 34: 973-95.
62. Rosa TT, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens 2000; 18: 645-54.
63. Keane WF, Proteinuria: Its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S97-S105.
64. Baumelou A, Bruckert E, Bagnis C, Deray G. Renal disease in cardiovascular disorders: an underrecognized problem. Am J Nephrol 2005; 25: 95-105.
65. Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001; 38: 1372-5.
66. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 2001; 9: 827-33.
67. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
68. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-8.
69. Marshall SM. Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. Diabetic Med 1999; 16: 358-72.
70. Gerstein HC, Mann JFE, Yi Q, et al. For the HOPE study investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
71. Hillege HL, Fidler V, Diercks GF, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-82.
72. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003; 139: 901-6.
73. Ibsen H, Wachtell K, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Kidney Int 2004; 66: S56-8.
74. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
75. Toto RD. Proteinuria and hypertensive nephrosclerosis in African-Americans. Kidney Int 2004; 66: S102-4.
76. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients. Losartan Intervention for Endpoint Reduction in Hypertension study. Hypertension 2005; 45: 198-202.
77. El-Atat F, McFarlane SI, Sowers JR. Diabetes, hypertension and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004; 6: 215-23.
78. Marshall SM, Alberti KG. Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and non-insulin-dependent diabetes. Q J Med 1989; 70: 61-71.
79. Deferrari G, Repetto M, Calvi C, Ciabattoni M, Rossi C, Robaudo C. Diabetic nephropathy from micro- to macroalbuminuria. Nephrol Dial Transplant 1998; 13: 11-5.
80. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001; 50: 2842-49.
81. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Clin Biochem 2002; 33: 487-94.
82. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1413-8.
83. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100.
84. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and non-diabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care 2000; 23: B35-9.
85. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-33.
86. Winocour PH, Harland JO, Millar JP, Laker MF, Alberti KG. Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis 1992; 93: 71-81.
87. Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004; 17: 986-93.
88. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-97.
89. Hillege HL, Janssen WM, Bak AA, et al. Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519-26.
90. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kid Dis 2003; 42:466-73.
91. Yuyun MF, Khaw KT, Luben R, et al. European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004; 33: 189-98.
92. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodelling. Cardiovasc Res 2004; 63: 423-32.
93. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107:984-91.
94. Li RK, Mickle DA, Weisel RD, et al. Overexpression of transforming growth factor-beta 1 and insulin-like growth factor-1 in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997; 96:874-81.
95. Li G, Li RK, Mickle DA, et al. Elevated insulin-like growth factor-I and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic cardiomyopathy: a possible mechanism. Circulation 1998; 98:11144-9.
96. Pauschinger M, Knopf D, Petschauer S, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/ III ratio. Circulation 1999; 99: 2750-6.
97. Thompson NL, Bazoberry F, Speir EH, et al. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth factors 1988; 1: 91-9.
98. Casscells W, Bazoberry F, Speir E, et al. Transforming growth factor-β1 in normal heart and in myocardial infarction. Ann NY Acad Sci 1990; 593: 148-60.
99. Hao J, Ju H, Zhao S, Junaid A, Scammel-La Fleur T, Dixon MC. Elevation of expression of Smads 2, 3, and 4, decorin and TGF-β in the chronic phase of myocardial infarct scar healing. J Mol Cell Cardiol 1999; 31: 667-78.
100. Wünsch M, Sharma HA, Markert T, et al. In situ localisation of transforming growth factor beta 1 in porcine heart: enhanced expression after chronic coronary artery occlusion. J Mol Cell Cardiol 1991; 23:1051-62.
101. Li JM, Brooks G. Differential protein expression and subcellular distribution of TGF beta 1, beta 2 and beta 3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol 1997; 29:2213-24.
102. Schultz JEJ, Witt SA, Glascock BJ, et al. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787-96.
103. Diebold RJ, Eis MJ, Yin M, et al. Early-onset multifocal inflammation in the transforming growth factor, beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 1995; 92: 12215-12219.
104. Brooks WW, Conrad CH. Myocardial fibrosis in transforming growth factor heterozygous mice. J Mol Cell Cardiol 2000; 32: 187-95.
105. Wildenthal K, Mueller EA. Increased myocardial cathepsin D activity during regression of thyrotoxic cardiac hypertrophy. Nature 1974; 249: 478-79.
106. Suzuki H, Schaefer L, Ling H, et al. Precention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995; 15: 129-36.
107. Osicka TM, Kiriazis Z, Pratt LM, Jerums G, Comper WD. Ramipril and aminoguanidine restore renal lysosomal prcessing in streptozotocin diabetic rats. Diabetologia 2001; 44: 230-6.
108. Osicka TM, Yu Y, Panagiotopoulos S, et al. Prevention of albuminuria by aminoguanidine or ramipril in STZ-diabetic rats is associated with the normalisation of glomerular protein kinese C. Diabetes 2000; 19: 87-93.
109. Dahlöf B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995; 9: S37-44.
110. Suzuki H, Schaefer L, Ling H, et al. Precention of cardiac hypertrophy in experimental chronic renal failure by long-term ACE inhibitor administration: potential role of lysosomal proteinases. Am J Nephrol 1995; 15: 129-36.
111. Bohm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163-164: 217-21.
112. Gohlke P, Linz W, Scholkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28: 397-402.
113. Inada Y, Wada T, Ojima M, et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19:1079-99.
114. Liu YH, Yang XP, Sharov VG, et al. Effects if angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-35.
115. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998; 16: S23-9.
116. Flather MD, Yusuf S, Kober L, et al. Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.
117. Cohn JN, Tognoni G. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
118. Kim S, Yoshiyama M, Izumi T, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodelin, cardiac function, and survivial in rat heart failure. Circulation 2001; 103: 148-54.
119. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2098-107.
120. Nakamura Y, Yoshiyama M, Omura T, et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodelling in rat myocardial infarction. Cardiovasc Res 2003; 57: 48-54.
121. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Eng J Med 2003; 349: 1893-906.
122. Pfeffer MA, Swedberg K, Granger CB, et al CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362: 759-66.
123. McMurray JJV, Östergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left vetricular dysfunction taking angiotensin-converting enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-71.
124. 1, suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93: 1172-8.
125. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346: 371-4.
126. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-4.
127. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-5.
128. Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res. 2005; 65: 694-701.
129. Pedrinelli R, Giamietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-8.
130. Stehouwer CDA, Nauta JJP, Zeldenhurst GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
131. Stehouwer CDA. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19: 778-81.
132. Allain F, Vanpouille C, Denys A, Pakula R, Carpentier M, Mazurier J. Involvement of GAGs in the activity of pro-inflammatory factors. Adv Exp Med Biol 2003; 535: 95-106.
133. Rops ALWMM, van der Vlag J, Lensen JFM, et al. Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 2004; 65: 768-85.
134. Comper WD, Osicka TM, Russo LM. Renal filtration, transport, and metabolism of albumin and albuminuria. In 'The Kidney: Physiology and Pathophysiology.' 4th edition. Eds, Alpern R and Hebert S. Chap 82, Elsevier/Academic Press, 2007 (in Press).